Board of Directors

Home / Company / Board of Directors

Board of Directors

  • Partnerships-tab05
    Caren Mason
  • Partnerships-tab04
    Craig Asher
  • Partnerships-tab02
    Paul Conley, PhD
  • Partnerships-tab03
    Dr. Carolyn Compton, MD, PhD
  • Partnerships-tab01
    Bill W. Colston, PhD
  • Jason_Hong2016
    Jason Hong, PhD

Bill W. Colston, PhD

CEO, HealthTell

Dr. Bill Colston was previously the CEO and scientific founder of QuantaLife Inc.™, a successful biotechnology startup company. QuantaLife developed the most accurate genetic analysis system in the world, now sold internationally (droplet digital PCR™). Dr. Colston raised multiple rounds of private funding, moving from concept to manufactured product in a fraction of the time of comparable companies in this space. QuantaLife grew exponentially during his tenure, from the four scientific founders during the inception in 2008 to over sixty employees by the time it was sold to BioRad in 2011. Prior to QuantaLife, Dr. Colston worked within the University of California (UC) National Labs for almost 20 years, ultimately serving in multiple different senior leadership roles. A prolific scientific writer and inventor, he has authored numerous publications and patents. Dr. Colston received his BS in biology from the University of Texas, Austin, in 1989 and his Ph.D. in biomedical engineering from the University of California, Davis, in 1997.

Caren Mason

Caren Mason has built a track record of excellence in more than 25 years of healthcare company leadership for large corporations, small public companies and start-up firms in life sciences, health care and medical devices. Her strength in strategy, market development and go-to-market commercialization are welcome contributions to the long term growth of HealthTell.

She has served as CEO of firms including: Verinata Health, a leading provider of non-invasive prenatal genetic testing services, Quidel, a public rapid immunoassay and molecular diagnostics test company and MiraMedica, Inc., a private computer-aided detection mammography systems company. Additionally, Ms Mason held leadership roles at eMed Technologies, GE Healthcare, and Bayer AG/AGFA as well as Baxter Healthcare.

Caren Mason is a graduate of Indiana University. She currently serves on the Board of STAAR Surgical, a public ophthalmic refractive surgery company where she is inaugural Chair of the Quality & Regulatory Committee and a member of the Audit Committee.

Craig Asher

Principal, Vital Venture Capital LLC

Craig Asher has had a successful track record of developing software companies. Over the past ten years he has been a key team member in three successful software startups: Commerce One; Trigo Technologies; and the internal IBM startup for InfoSphere Traceability Server. He has guided major software implementations at over 50 customers in markets including retail, medical products, pharmaceuticals, and general distribution. Following Trigo’s sale to IBM, Craig formed a new startup group within IBM to build a new product for information management software for sensor data. Craig’s role in the new venture was the product strategist, product manager, and implementation manager. Craig has enjoyed co‐chairing several working groups in international standards bodies. He has one issued US patent (7,866,543). He also has extensive experience in marketing strategy, product management, product development, services delivery, business development, and technical sales for growing software companies. Craig did his undergraduate work at Stanford University, and completed his MBA and Masters in Industrial Engineering at Northwestern University.

Dr. Carolyn Compton, MD, PhD

CMO, NBDA

Dr. Carolyn Compton is an academic pathologist who received her MD and PhD degrees from Harvard Medical School. At ASU, she is the Chief Medical and Science Officer of the National Biomarkers Development Alliance, a member of the Biodesign Institute and the Chief Medical Officer of the Complex Adaptive Systems Initiative. Her research interests are related to colon cancer, bio-­banking and biomarkers development.

She was a professor of pathology at Harvard and Massachusetts General Hospital, Chair of Pathology at McGill University from 2000 to 2005, and Director of the Office of Biorepositories and Biospecimen Research at the National Cancer Institute until 2012. She is the past CEO and President of the Critical Path Institute. Compton is an adjunct professor of pathology at both the University of Arizona and Johns Hopkins, and research associate at Mayo Clinic.

Paul Conley, PhD

Managing Director, Paladin Capital Group

Dr. Conley leads new investments for the firm while serving as an active Director on many of Paladin’s portfolio company Boards. Paul joined the Paladin team after more than 15 years of previous R&D and entrepreneurial experience. As founding CEO of BrightScale, he led the commercialization of a patented multi-core microprocessor technology in the HDTV market. As founding CEO of Appfluent Technology, he led the commercialization of patented in-memory distributed database technologies in the enterprise IT market. Prior to taking the entrepreneurial route, he spent nearly a decade in multidisciplinary R&D roles in the areas of high-performance computing, applied physics and biomedical engineering, including postdoctoral positions at the Los Alamos National Laboratory. Paul earned a PhD in Computational Physics and an MS in Bioengineering from UCSD, as well as an MS and BS in Mechanical and Aerospace Engineering from the University of Virginia.

Bill W. Colston, PhD

HealthTell, Inc.

(See Bio information under Our Leadership)